Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: Persistent effects after withdrawal

Life Sciences

Volumn 75, Issue 7, 2004, Pages 881-891

  Sevilla, María A ^a   Voces, Felipe ^a   Carrón, Rosalía ^a   Guerrero, Estela I ^b   Ardanaz, Noelia ^a   San Román, Luis ^a   Arévalo, Miguel A ^c   Montero, María J ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSIDAD DE PANAMÁ   (Panama)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Amlodipine; Fibrosis; Hypertrophy; Spontaneously hypertensive rats; Treatment withdrawal

Indexed keywords

AMLODIPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; DRUG WITHDRAWAL; FIBROSIS; HEART LEFT VENTRICLE; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 2942588700     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2004.04.004     Document Type: Article

References (42)

1. Agabiti-Rosei E. Evaluation of the cardiac effects of antihypertensive agents. Journal of Cardiovascular Pharmacology. 23(Suppl. 5):1994;S42-S48
2. Amenta F., Peleg E., Tomassoni D., Sabbatini M., Rosenthal T. Effect of Treatment With Lercanidipine on Heart of Cohen-Rosenthal Diabetic Hypertensive Rats. Hypertension. 41:2003;1330-1335
3. Bishop J.E., Kiernan L.A., Montgomery H.E., Gholke P., McEwan J.R. Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats. Cardiovascular Research. 47(1):2000;57-67
4. Bishop J.E., Rhodes S., Laurent G.J., Low R.B., Stirewalt W.S. Increased collagen synthesis and decreased collagen degradation in right ventricular hypertrophy induced by pressure overload. Cardiovascular Research. 28:1994;1581-1585
5. Biston P., Melot C., Degaute J.P., Clement D., Quoidbach A. Prolonged antihypertensive effect of amlodipine: a prospective double-blind randomized study. Blood Pressure. 8(1):1999;43-48
6. Brilla C.G., Scheer C., Rupp H. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. Journal of Hypertension. 15(6):1997;S13-S19
7. Brilla C.G., Scheer C., Rupp H. Angiotensin II and intracellular calcium of adult cardiac fibroblasts. Journal of Molecular and Cellular Cardiology. 30(6):1998;1237-1246
8. Brilla C.G. Regression of myocardial fibrosis in hypertensive heart disease: diverse effects of various antihypertensive drugs. Cardiovascular Research. 46:2000;324-331
9. Burges R.A., Dodd M.D., Gardiner D.G. Pharmacological profile of amlodipine. American Journal of Cardiology. 64:1989;10I-20I
10. Civantos B., Aleixandre A. Effect of dietary calcium supplements and amlodipine on growth, arterial blood pressure, and cardiac hypertrophy of spontaneously hypertensive rats. Clinical and Experimental Hypertension. 25(8):2003;495-508
11. De Paoli P., Cerbai E., Koidl B., Kirchengast M., Sartiani L., Mugelli A. Selectivity of Differents Calcium Antagonists on T- and L-Type Calcium Currents in Guinea-Pig Ventricular Myocytes. Pharmacological Research. 46(6):2002;491-497
12. Frohlich E.D. Overview of haemodynamic and non-haemodynamic factors associated with LVH. Journal of Molecular and Cellular Cardiology. 6:1994;279-292
13. Frohlich E.D., Apstein C., Chobanian A.V., Devereux R.B., Dustan H.P., Dzau V., Fauad-Tarazi F., Horan M.J., Marcus M., Massie B. The heart in hypertension. New England Journal of Medicine. 327(14):1992;998-1008
14. Fulton R., Hutchinson E., Morgan-Jones A. Ventricular weight in cardiac hypertrophy. British Heart Journal. 14:1952;413-420
15. Ganau A., Devereux R.B., Roman M.J., de Simone G., Pickering T.G., Saba P.S., Vargiu P., Simongini I., Laragah J.H. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. Journal of American College Cardiology. 19(7):1992;1550-1558
16. García del Moral R. Coloraciones para fibras colágenas y elásticas del tejido conjuntivo. Coloraciones para sustancias amiloideas. Laboratorio de Anatomía Patológica. 1993;181-182 Mc Graw-Hill Interamericana, Madrid
17. Kaplinsky E. Significance of left ventricular hypertrophy in cardiovascular morbidity and mortality. Cardiovascular Drugs and Therapy. 8:1994;549-556
18. Klaus D. The role of calcium antagonists in the treatment of hypertension. Journal of Cardiovascular Pharmacology. 20(Suppl. 6):1992;S5-S14
19. Kojima M., Shiojima I., Yamazaki T., Komuro I., Zou Z., Wang Y., Mizuno T., Ueki K., Tobe K., Kadowaki T. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro. Circulation. 89(5):1994;2204-2211
20. Lüscher T.F., Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension: a reappraisal. Drugs. 55:1998;509-517
21. Mann D.L., Kent R.L., Cooper G. Load regulation of the properties of adult feline cardiocytes: Growth induction by cellular deformation. Circulation Research. 64:1989;1079-1090
22. Marque V., Grima M., Kieffer P., Capdeville-Atkinson C., Atkinson J., Lartaud-Idjouadiene I. Withdrawal reveals lack of effect of prolonged antihypertensive treatment on intrinsic aortic wall stiffness in senescent spontaneously hypertensive rats. Clinical and Experimental Pharmacology and Physiology. 19(10):2002;898-904
23. 2+ channels in ventricular cells from hypertrophied rat hearts. Journal of Molecular and Cellular Cardiology. 31:1999;1617-1625
24. Oparil S., Calhoun D.A. The calcium antagonists in the 1990s: an overview. American Journal of Hypertension. 4:1991;422S-429S
25. Paull J.R.A., Widdop R.E. Persistent cardiovascular effects of chronic rennin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats. Journal of Hypertension. 19:2001;1393-1402
26. Ramires F.J., Sun Y., Weber K.T. Myocardial fibrosis associated with aldosterone or angiotensin II administration: attenuation by calcium channel blockade. Journal of Molecular and Cellular Cardiology. 30(3):1998;475-483
27. Sakata Y., Hoit B.D., Liggett S.B., Walsh R.A., Dorn G.W. Decompensation of Pressure-Overload Hypertrophy in Gα0q-Overexpressing Mice. Circulation. 97:1998;1488-1495
28. Sandmann S., Bohle R.M., Dreyer T., Unger T. The T-type calcium channel blocker mibefradil reduced interstitial and perivascular fibrosis and improved hemodynamic parameters in myocardial infarction-induced cardiac failure in rats. Virchows Archiv. 436:2000;147-157
29. Skov K., Fenger-Gron J., Mulvany M.J. Effects of an Angiotensin- Converting Enzyme Inhibitor, a Calcium Antagonist, and an Endothelin Receptor Antagonist on Renal Afferent Arteriolar Structure. Hypertension. 28:1996;464-471
30. Stepien O., Iouzalen L., Herembert T., Zhu D.L., Marche P. Amlodipine and vascular hypertrophy. International Journal of Cardiology. 62(Suppl. 2):1997;S79-S84
31. Struyker-Boudier H.A.J., Sits J.F.M., De Mey J.G.R. The pharmacology of calcium antagonists: a review. Journal of Cardiovascular Pharmacology. 15(Suppl. 4):1990;S1-S10
32. Suzuki M., Yamanaka K., Nabata H., Tachibana M. Long term effects of amlodipine on organ damage, stroke and life span in stroke prone spontaneously hypertensive rats. European Journal of Pharmacology. 228(5-6):1993;269-274
33. Triggle D.J. The physiological and pharmacological significance of cardiovascular T-type voltage-gated calcium channels. American Journal of Hypertension. 11:1998;80S-87S
34. 2+ Antagonists on Left Ventricle Hypertrophy and Coronary Changes in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology. 41:2003;544-552
35. Van Zwieten P.A. The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy. Cardiovascular Research. 45:2000;82-91
36. Varo N., Etayo J.C., Zalba G., Beaumont J., Iraburu M.J., Montiel C., Gil M.J., Monreal I., Diez J. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. Journal of Hypertension. 17(1):1999;107-111
37. Watanabe M., Kawaguchi H., Onozuka H., Mikami T., Urasawa K., Okamoto H., Watanabe S., Abe K., Kitabatake A. Chronic effects of enalapril and amlodipine on cardiac remodeling in cardiomyopathic hamster hearts. Journal of Cardiovascular Pharmacology. 32(2):1998;248-259
38. Weber K.T., Sun Y., Tyagi S.C., Cleutjens J.P. Collagen network of the myocardium: function, structural remodeling and regulatory mechanisms. Journal of Molecular and Cellular Cardiology. 26(3):1994;279-292
39. Witte K., Huser L., Knotter B., Heckmann M., Schiffer S., Lemmer B. Normalisation of blood pressure in hypertensive TGR(mREN2)27 rats by amlodipine v. enalapril: effects on cardiac hypertrophy and signal transduction pathways. Naunyn Schmiedebergs Archives of Pharmacology. 363(1):2001;101-109
40. Wood A.J.J. Calcium antagonists. Pharmacologic differences and similarities. Circulation. 80(Suppl. IV):1989;184-188
41. Yamazaki T., Komuro I., Zou Y., Kudoh S., Shiojima I., Mizuno T., Hiroi Y., Nagai R., Yazaki Y. Efficient Inhibition of the Development of Cardiac Remodeling by a Long-Acting Calcium Antagonist Amlodipine. Hypertension. 31(Part 1):1998;32-38
42. 2+ channel antagonist, amlodipine, in spontaneously hypertensive rats at established stage of hypertension. Japanese Journal of Pharmacology. 77(1):1998;79-87